Cargando…

In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren

Ataluren promotes ribosomal readthrough of premature termination codons in mRNA which result from nonsense mutations. In vitro studies were performed to characterize the metabolism and enzyme kinetics of ataluren and its interaction potential with CYP enzymes. Incubation of [(14)C]‐ataluren with hum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Ronald, Ma, Jiyuan, Hwang, Seongwoo, Moon, Young‐Choon, Welch, Ellen M., Weetall, Marla, Colacino, Joseph M., Almstead, Neil, Babiak, John, Goodwin, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083565/ https://www.ncbi.nlm.nih.gov/pubmed/32196986 http://dx.doi.org/10.1002/prp2.576

Ejemplares similares

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

Ataluren suppresses a premature termination codon in an MPS I-H mouse
por: Wang, Dan, et al.
Publicado: (2022)

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation
por: Weetall, Marla, et al.
Publicado: (2016)

Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform
por: Cao, Liangxian, et al.
Publicado: (2016)

Effect of Ataluren on dystrophin mutations
por: Berger, Joachim, et al.
Publicado: (2020)

Caffeine boosts Ataluren's readthrough activity
por: Lentini, Laura, et al.
Publicado: (2019)

Treatment with Ataluren for Duchene Muscular Dystrophy
por: Morkous, Sameh S.
Publicado: (2020)

Ataluren treatment of patients with nonsense mutation dystrophinopathy
por: Bushby, Katharine, et al.
Publicado: (2014)

Long term treatment with ataluren—the Swedish experience
por: Michael, Eva, et al.
Publicado: (2021)

The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines
por: Luban, Jeremy, et al.
Publicado: (2021)

Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016)

Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia
por: Djayet, Celia, et al.
Publicado: (2020)

Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
por: Michorowska, Sylwia
Publicado: (2021)

Inhibition and induction of CYP enzymes in humans: an update
por: Hakkola, Jukka, et al.
Publicado: (2020)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations
por: Samanta, Ananya, et al.
Publicado: (2019)

Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms
por: Ng, Martin Y., et al.
Publicado: (2021)

Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort
por: Kong, Ronald, et al.
Publicado: (2020)

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential
por: Friesen, Westley J., et al.
Publicado: (2018)

The nucleoside analog clitocine is a potent and efficacious readthrough agent
por: Friesen, Westley J., et al.
Publicado: (2017)

Substrate Selectivity of Coumarin Derivatives by Human CYP1 Enzymes: In Vitro Enzyme Kinetics and In Silico Modeling
por: Juvonen, Risto O., et al.
Publicado: (2021)

Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes
por: Bolze, Florian, et al.
Publicado: (2017)

Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy
por: Bitetti, Ilaria, et al.
Publicado: (2021)

Kinetic Characteristics of Curcumin and Germacrone in Rat and Human Liver Microsomes: Involvement of CYP Enzymes
por: Su, Shaofeng, et al.
Publicado: (2022)

Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder
por: Devinsky, Orrin, et al.
Publicado: (2021)

Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination
por: Huang, Shijie, et al.
Publicado: (2022)

In vitro cytochrome P450‐ and transporter‐mediated drug interaction potential of 6β‐hydroxy‐21‐desacetyl deflazacort—A major human metabolite of deflazacort
por: Ma, Jiyuan, et al.
Publicado: (2021)

Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
por: Finkel, Richard S., et al.
Publicado: (2013)

One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?
por: Ruggiero, Lucia, et al.
Publicado: (2018)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
por: Dori, Amir, et al.
Publicado: (2021)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
por: Dori, Amir, et al.
Publicado: (2022)

Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia
por: Branstrom, Arthur, et al.
Publicado: (2022)

Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors
por: Rahman, Mohammad A., et al.
Publicado: (2017)

The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β‐eudesmol in human liver: Reaction phenotyping and enzyme kinetics
por: Muhamad, Nadda, et al.
Publicado: (2023)

Identification of benzazole compounds that induce HIV-1 transcription
por: Graci, Jason D., et al.
Publicado: (2017)

A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
por: McElroy, Stuart P., et al.
Publicado: (2013)

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
por: Jernigan, Finith, et al.
Publicado: (2021)

Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2018)

Induction of Cyp450 enzymes by 4-thiazolidinone-based derivatives in 3T3-L1 cells in vitro
por: Szychowski, Konrad A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8udg2sii2rvlntnc7mm1reqghk